Protalex Inc. | Income Statement

Fiscal year is June-May. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cost of Goods Sold (COGS) incl. D&A
1.00
1.00
1.00
1.00
1.00
1
Gross Income
1.00
1.00
1.00
1.00
1.00
1
SG&A Expense
5,619.30
11,567.50
11,298.00
8,980.10
4,005.20
4,423.60
EBIT
5,620.30
11,568.50
11,299.00
8,981.10
4,006.20
4,424.60
Interest Expense
663.90
283.70
320.80
434.30
557.50
611.50
Pretax Income
6,280.20
11,852.20
11,619.80
9,415.50
4,563.70
5,036.20
Consolidated Net Income
6,280.20
11,852.20
11,619.80
9,415.50
4,563.70
5,036.20
Net Income
6,280.20
11,852.20
11,619.80
9,415.50
4,563.70
5,036.20
Net Income After Extraordinaries
6,280.20
11,852.20
11,619.80
9,415.50
4,563.70
5,036.20
Net Income Available to Common
6,280.20
11,852.20
11,619.80
9,415.50
4,563.70
5,036.20
EPS (Basic)
0.33
0.45
0.40
0.33
0.16
0.15
Basic Shares Outstanding
18,926.60
26,222.60
28,767.60
28,767.60
28,767.60
33,546.90
EPS (Diluted)
0.33
0.45
0.40
0.33
0.16
0.15
Diluted Shares Outstanding
18,926.60
26,222.60
28,767.60
28,767.60
28,767.60
33,546.90
EBITDA
5,619.30
11,567.50
11,298.00
8,980.10
4,005.20
4,423.60
Non-Operating Interest Income
4.00
0.00
0.00
0.00
0.00
-

About Protalex

View Profile
Address
131 Columbia Turnpike
Florham Park New Jersey 07932
United States
Employees -
Website http://www.protalex.com
Updated 07/08/2019
Protalex, Inc. is a development stage company which focuses on the development of a class of biopharmaceutical drugs for treating autoimmune and inflammatory diseases including rheumatoid arthritis. Its product includes PRTX-100, formulated with purified staphylococcal protein A, which is an immune modulating protein produced by bacteria. The company was founded by John E.